StrongRoom AI raises $2M in comeback after collapse and administration
What's the deal? StrongRoom AIDealroom has a profile for this one. Try Dealroom →, an Australian controlled-substance management startup, has raised $2 million in a late-stage round backed by pharmacy franchise owners. Existing venture capital investors EVP CapitalDealroom has a profile for this one. Try Dealroom → and Artesian Capital ManagementDealroom has a profile for this one. Try Dealroom → also took part.
Why now? The raise follows the company's acquisition out of administration by Brisbane entrepreneur Joe ZhouDealroom has a profile for this one. Try Dealroom → in June 2026. It marks a step-up from its previous round, part of a broader turnaround effort.
What's the endgame? The capital will fund product development and customer growth. StrongRoom AI plans to double down on pharmacy clients while expanding into hospitals, ambulance services, and aged care facilities.
The new money is led by franchisees from pharmacy chains TerryWhite ChemmartDealroom has a profile for this one. Try Dealroom → and Priceline, alongside figures from the medicinal cannabis and hospital sectors. Zhou remains the largest shareholder and has taken on the chief executive role, alongside running his 40-person startup, Aceso GroupDealroom has a profile for this one. Try Dealroom →.
The numbers: Zhou's restructuring cut monthly losses from roughly $800,000 to near breakeven — without layoffs. He discontinued non-core products, sold assets, and replaced the board and governance structures.
What could go wrong? StrongRoom AI's past is troubled. Founded in 2017, it collapsed in 2025 after EVP Capital, its largest venture capital backer, accused former executives of misrepresenting finances by classifying grants and loans as revenue. A liquidator is now examining the conduct of some former directors.
Despite the tarnished reputation among investors, Zhou kept the StrongRoom AI name, arguing the brand still holds standing among healthcare professionals. The software helps regulated organisations manage distribution of controlled substances such as fentanyl and medical cannabis.
The signal: The involvement of pharmacy and healthcare operators — not just VCs — points to industry demand for the underlying technology, even after the company's fall. Zhou says he did not buy StrongRoom AI for a quick resale, framing the raise as a bet on rebuilding rather than flipping.
Image credit: Generated with Gemini
Read more: Startup Researcher
